Takeda Neuroscience is driven by the unmet need of patients with neurologic and psychiatric diseases. Our mission is to bring innovative and potentially disease-modifying medicines to these individuals.
Our dedication extends beyond our marketed products and research efforts. We are committed to raising awareness for these conditions, building strategic partnerships with both industry and advocacy, educating patients and physicians, and broadening access to therapies.
Looking to the future, Takeda is setting a high bar for innovation and is focused on potential investigative options in rare neurological conditions with significant unmet needs.
*NOTE: These are not the complete diagnostic criteria and having some or all of these symptoms does not mean you have any one of these diseases. Diagnosis should be based on a complete history and evaluation of the patient. Only a trained healthcare professional can diagnose these disorders. If you or a loved one is concerned about any of these disorders, please consult your healthcare professional.
1 American Psychiatric Association, American Psychiatric Association, eds. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. American Psychiatric Association; 2013.
2 James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(18)32279-7
3 Kessler RC, Berglund PA, Chiu WT, et al. The Prevalence and Correlates of Binge Eating Disorder in the World Health Organization World Mental Health Surveys. Biological Psychiatry. 2013;73(9):904-914. doi:10.1016/j.biopsych.2012.11.020
4 Hudson JI, Hiripi E, Pope HG Jr, et al. The Prevalence and Correlates of Eating Disorders in the National Comorbidity Survey Replication [published correction appears in Biol Psychiatry. 2012;72(2):164]. Biol Psychiatry. 2007;61(3):348‐358.
5 Strzelczyk A, Kalski M, Bast T, et al. Burden-of-illness and Cost-driving Factors in Dravet syndrome Patients and Carers: A prospective, multicenter study from Germany. European Journal of Paediatric Neurology. 2019;23(3):392-403. doi:10.1016/j.ejpn.2019.02.014
6 Anwar A, Saleem S, Patel UK, Arumaithurai K, Malik P. Dravet Syndrome: An Overview. Cureus. 2019;11:e5006. doi:10.7759/cureus.5006
7 Dravet C. The core Dravet syndrome phenotype: Core Dravet Syndrome. Epilepsia. 2011;52:3-9. doi:10.1111/j.1528-1167.2011.02994.x
8 Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurology. 2009;8(1):82-93. doi:10.1016/S1474-4422(08)70292-8
9 Crumrine P. Lennox-Gastaut Syndrome. Journal of Child Neurology. 2001;17:S70-S75.
10 Sateia MJ. International Classification of Sleep Disorders- Third Edition. Chest. 2014;146:1387–94
11 Sturzenegger C. The Clinical Spectrum of Narcolepsy with Cataplexy: a reappraisal. Journal of Sleep Research. 2004;13:395-406.
12 Roth T, Dauvilliers Y, Mignot E, et al. Disrupted Nighttime Sleep in Narcolepsy. Journal of Clinical Sleep Medicine. 2013;9:955-965.
13 Dauvilliers Y et al. Measurement of Narcolepsy Symptoms: the narcolepsy severity scale. Neurology. 2017;88:1358-1365.
14 Mahoney C et al. The Neurobiological Basis of Narcolepsy. Nat Rev Neurosci. 2019;20:83-93.
15 A Study of TAK-994 in Participants With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 [NT1] or Narcolepsy Type 2 [NT2]). ClinicalTrials.gov. Published April 1, 2021. https://clinicaltrials.gov/ct2/show/NCT04096560
16 Kalia LV, Lang AE. Parkinson’s disease. The Lancet. 2015;386(9996):896-912. doi:10.1016/S0140-6736(14)61393-3
17 Postuma R, Berg D, Stern M et al. MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders. 2015;30(12):1591-1601. doi:10.1002/mds.26424
18 Hiseman JP, Fackrell R. Caregiver Burden and the Nonmotor Symptoms of Parkinson’s Disease. In: International Review of Neurobiology. Vol 133. Elsevier; 2017:479-497. doi:10.1016/bs.irn.2017.05.035